Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global enteric empty capsules market was valued at USD 86.6 million in 2024. The market is projected to grow to USD 254 million by 2031, exhibiting a compound annual growth rate (CAGR) of 17.0% during the forecast period.
Enteric empty capsules are a specialized pharmaceutical dosage form designed to resist dissolution in the acidic environment of the stomach. Their primary function is to prevent the active ingredient inside from being destroyed or degraded by gastric acid, ensuring targeted drug release in the higher pH environment of the intestine. This technology is crucial for the effective delivery of acid-labile drugs, certain probiotics, and nutrients.
The market is experiencing significant growth, primarily driven by the increasing global demand for pharmaceutical products that require targeted release. Furthermore, the rising consumer preference for capsule-based dietary supplements and the expansion of the pharmaceutical industry in emerging economies are key contributors. The market is highly concentrated, with the top five players holding a combined market share of approximately 90%. This dominance is held by key industry players such as Capsugel and CapsCanada. Geographically, China is the largest market, accounting for about 55% of the global share, while North America and Europe together represent around 40%.
Rising Prevalence of Chronic Diseases
The global increase in chronic conditions such as inflammatory bowel disease (IBD), acid-related disorders, and diabetes is a primary driver for the enteric empty capsules market. These capsules are specifically designed to resist dissolution in the acidic environment of the stomach, ensuring targeted drug release in the intestine. This targeted delivery is crucial for the efficacy of drugs like proton pump inhibitors, pancreatic enzymes, and certain biologics, which are sensitive to gastric acid. The growing patient population requiring such therapies directly fuels the demand for advanced delivery systems like enteric capsules.
Advancements in Capsule Technology
Technological innovations in polymer science and capsule manufacturing are significantly propelling the market forward. The development of new enteric polymers, such as hypromellose phthalate (HPMCP) and cellulose acetate phthalate (CAP), offers improved performance and reliability. Furthermore, manufacturers are innovating with plant-based and halal-certified capsules to cater to diverse consumer preferences and regulatory requirements. These advancements enhance the functionality and broaden the appeal of enteric capsules in the pharmaceutical and nutraceutical industries.
➤ The global nutraceutical sector's expansion, valued at over $400 billion, is increasingly adopting enteric-coated capsules for sensitive ingredients like probiotics and omega-3 fatty acids to ensure they reach the intestines intact, significantly boosting market growth.
Additionally, stringent regulatory mandates for improved drug safety and efficacy are compelling pharmaceutical companies to adopt specialized delivery systems. Enteric capsules help mitigate side effects like gastric irritation and ensure optimal bioavailability, aligning with these regulatory standards. The proven benefits and regulatory support create a strong, sustained demand driver for the market.
MARKET CHALLENGES
High Production Costs and Complex Manufacturing
The production of enteric empty capsules is more complex and expensive compared to standard gelatin or HPMC capsules. The process involves specialized equipment for applying the enteric coating and requires strict control over environmental conditions to ensure the coating's integrity and performance. The raw materials, particularly high-quality enteric polymers, also carry a premium cost. These factors collectively result in a higher final product price, which can be a barrier for cost-sensitive markets and smaller manufacturers.
Other Challenges
Regulatory Hurdles and Compliance
Enteric capsules are classified as drug delivery systems and are subject to rigorous regulatory scrutiny by agencies like the FDA and EMA. Each new formulation or material change requires extensive stability testing, bioequivalence studies, and approval processes, which are time-consuming and costly. Navigating the varying regulatory landscapes across different countries adds another layer of complexity for global market players.
Competition from Alternative Technologies
The market faces competition from other advanced drug delivery technologies, such as delayed-release tablets, multiparticulate systems, and gastro-resistant micropellets. These alternatives sometimes offer similar benefits of targeted release and can be more cost-effective for certain applications, posing a challenge to the market share of enteric capsules.
Price Sensitivity in Emerging Markets
While demand for pharmaceutical products is growing in emerging economies, high price sensitivity remains a significant restraint for the enteric empty capsules market. The premium cost of enteric-coated formulations can limit their adoption in public healthcare systems and among price-conscious consumers in regions like Asia-Pacific and Latin America. Manufacturers face pressure to reduce costs without compromising quality to penetrate these high-growth but cost-sensitive markets effectively.
Limited Shelf Life and Stability Concerns
Enteric coatings can be sensitive to humidity and temperature variations during storage and transportation, potentially leading to reduced shelf life or compromised performance if not handled correctly. This necessitates sophisticated supply chain management and packaging solutions, adding to the overall cost and complexity. Concerns about long-term stability under varying climatic conditions can deter some pharmaceutical companies from widely adopting these capsules for their products.
Expansion in Biologics and High-Potency Drugs
The rapid growth of the biologics market presents a substantial opportunity for enteric empty capsules. Many biologic drugs, including peptides and certain monoclonal antibodies, are highly susceptible to degradation in the stomach. Enteric capsules provide an ideal delivery system to protect these sensitive molecules and ensure their delivery to the absorption site in the intestine. With the biologics market projected to continue its strong growth, the demand for compatible, reliable capsules is expected to surge.
Rising Demand for Vegetarian and Halal-Certified Products
There is a growing consumer and pharmaceutical industry preference for plant-based and halal-certified products. This trend creates a significant opportunity for manufacturers of enteric capsules made from cellulose derivatives (HPMC) and pullulan, which are vegetarian and suitable for halal certification. Tapping into this demand allows companies to differentiate their products and access new market segments, particularly in regions with large Muslim populations and among health-conscious consumers globally.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Gelatin Type is the dominant segment, driven by its extensive historical use in pharmaceutical manufacturing, proven efficacy in providing reliable enteric release, and well-established, cost-effective production processes. However, the HPMC Type is experiencing significant growth momentum due to increasing consumer preference for vegetarian and halal-certified pharmaceutical products, as well as enhanced stability profiles for certain active ingredients, making it a key focus for innovation and future market expansion. |
| By Application |
|
Pharmaceutical holds a commanding lead, as enteric capsules are critical for protecting acid-sensitive drugs, ensuring targeted intestinal delivery, and enhancing patient compliance for a wide range of therapeutic treatments. The Health Supplements segment represents a high-growth area, fueled by consumer demand for advanced nutraceutical delivery systems that improve the bioavailability of probiotics and sensitive vitamins. The Others category shows niche potential for herbal formulations and specialty cosmetic ingredients requiring delayed or protected release mechanisms. |
| By End User |
|
Pharmaceutical Companies are the primary end users, leveraging enteric capsules for their extensive drug development pipelines and established over-the-counter and prescription product portfolios. The demand from Nutraceutical & Supplement Brands is accelerating rapidly, driven by product differentiation strategies and the need for advanced delivery solutions in a competitive market. Contract Manufacturing Organizations are also a significant segment, as they provide formulation and manufacturing services to both pharmaceutical and nutraceutical clients, creating a substantial demand for versatile and reliable enteric capsule supplies. |
| By Functional Property |
|
Delayed Release is the foundational and most widely adopted functional property, essential for protecting active ingredients from stomach acid and ensuring dissolution in the higher pH of the intestine. The Targeted Release segment is gaining prominence for specialized drugs and supplements that require release at precise locations within the gastrointestinal tract for optimal efficacy. Innovation is particularly strong in the Colon-Specific Release segment, which is critical for treating local colon diseases and for the delivery of biologics, representing a sophisticated and high-value application area. |
| By Distribution Channel |
|
Direct Sales (B2B) is the dominant channel, characterized by long-term supply agreements and close technical collaboration between capsule manufacturers and large pharmaceutical or nutraceutical companies. Distributors & Wholesalers play a crucial role in serving small to medium-sized enterprises and providing regional market access and logistical support. The emergence of specialized Online Platforms is a notable trend, offering greater transparency, easier access to a variety of capsule specifications, and streamlined procurement processes for research institutions and emerging brands, thereby expanding the market's reach. |
A Market Characterized by High Concentration and Specialized Manufacturing
The global enteric empty capsules market is a highly consolidated space, with the top five players collectively commanding approximately 90% of the market share. Leading this group is Capsugel, a Lonza company, which is recognized as a global leader in dosage form solutions. Capsugel's extensive portfolio and strong R&D capabilities in gelatin and HPMC-based enteric capsules solidify its dominant position, particularly in the critical pharmaceutical and health supplement sectors. This high concentration is driven by the significant capital investment, stringent regulatory requirements, and advanced technological expertise needed for the reliable production of capsules that can withstand gastric acid and dissolve in the intestinal environment.
Beyond the dominant players, the market includes several other significant manufacturers that serve specific regional markets or niche applications. Companies like Anhui Huangshan Capsule, Shanghai GS Capsule, and Qingdao Yiqing are pivotal in the Asia-Pacific region, especially in China, which constitutes the world's largest market for enteric capsules. Other players, such as Qualicaps (a Mitsubishi Chemical Group company) and ACG Associated Capsules, have strong international reach and focus on high-quality standards for the global pharmaceutical industry. These companies compete by offering specialized product lines, including both gelatin and HPMC (vegetarian) types, to meet diverse customer needs for drug delivery and supplement encapsulation.
List of Key Enteric Empty Capsules Companies ProfiledCapsugel (Lonza)
Suheung Co., Ltd.
Qualicaps (Mitsubishi Chemical Group)
Anhui Huangshan Capsule Co., Ltd.
Qingdao Yiqing Biotech Co., Ltd.
Levecaps
ACG Associated Capsules
Roxlor LLC
Sunil Healthcare Limited
Natural Capsules Limited
Bright Pharmacaps Inc.
Erawat Pharma Limited
Medi-Caps Ltd.
The global Enteric Empty Capsules market is demonstrating robust expansion, projected to grow from a valuation of $86.6 million in 2024 to US$ 254 million by 2031, at a compelling Compound Annual Growth Rate (CAGR) of 17.0%. This significant growth is primarily driven by the pharmaceutical industry's increasing reliance on these specialized capsules, which are designed to protect active ingredients from dissolution in the acidic environment of the stomach, ensuring targeted release in the intestinal tract. The rising prevalence of gastro-sensitive drugs and dietary supplements is a key factor propelling market demand. The market’s dynamics are characterized by strong regional concentration, technological evolution in capsule materials, and strategic consolidation among leading players.
Other TrendsRegional Market Dominance and Expansion
Geographically, the market is highly concentrated, with China representing the largest single market, accounting for approximately 55% of the global share. This dominance is attributed to the country's vast pharmaceutical manufacturing base and cost-effective production capabilities. North America and Europe collectively hold a significant share of about 40%, driven by advanced healthcare infrastructure, strict regulatory standards for drug delivery, and high consumer spending on health supplements. The competitive landscape is similarly consolidated, with the top five manufacturers including Capsugel, CapsCanada, Anhui Huangshan Capsule, Shanxi GS Capsule, and Qingdao Yiqing holding a combined market share of around 90%.
Product Type and Application Segmentation TrendsIn terms of product segmentation, Gelatin Type capsules continue to lead the market, holding a dominant share of approximately 75% due to their established manufacturing processes, cost-effectiveness, and excellent film-forming properties. However, the HPMC (Hydroxypropyl Methylcellulose) Type segment is gaining traction, especially in vegetarian and Halal/Kosher-certified markets. Regarding application, the Pharmaceutical sector is the largest end-user, followed by Health Supplements and other niches like Herb and Cosmetics. The trend indicates a growing adoption of enteric capsules for targeted nutrient delivery in supplements and for protecting sensitive botanical extracts, expanding the market beyond traditional pharmaceuticals.
Regional Analysis: Enteric Empty Capsules MarketNorth America
The North American enteric empty capsules market is characterized by high regulatory standards and a strong demand for advanced pharmaceutical formulations. The region, led by the United States, has a well-established pharmaceutical industry with a significant focus on innovative drug delivery systems. Strict FDA regulations ensure high-quality standards for enteric coatings, driving demand for reliably performing capsules from reputable suppliers. The high prevalence of chronic conditions requiring targeted release medications, coupled with substantial healthcare spending, sustains a robust market. There is a notable and growing consumer preference for vegetarian (HPMC) capsules, influencing both drug developers and capsule manufacturers. The presence of major pharmaceutical companies and a sophisticated biotech sector fuels demand for specialized capsules for clinical trials and new product launches.
Europe
Europe represents a mature yet steadily growing market for enteric empty capsules, underpinned by stringent regulatory oversight from the EMA and strong pharmaceutical manufacturing capabilities. Countries like Germany, France, and the United Kingdom are key contributors. The market is driven by a high awareness of gastrointestinal health and a strong generics industry that extensively utilizes enteric coatings for acid-labile drugs. There is a pronounced trend towards plant-based and halal-certified capsules, aligning with consumer preferences and regulatory pushes for sustainable and ethical products. The region's focus on personalized medicine and advanced clinical research creates demand for high-performance, custom-formulated enteric capsules. Consolidation among capsule manufacturers and close collaboration with drug formulators are key characteristics of the European landscape.
South America
The South American market for enteric empty capsules is emerging, showing potential driven by improving healthcare infrastructure and economic development, with Brazil and Argentina being the primary markets. Growth is fueled by an increasing burden of gastrointestinal diseases and a growing generics pharmaceutical sector. The market is price-sensitive, creating opportunities for cost-effective suppliers, often from the Asia-Pacific region. Regulatory harmonization efforts across the continent are gradually improving market access. Local production exists but is limited, leading to a significant reliance on imports to meet demand. The adoption of advanced drug delivery systems is slower compared to more mature markets, but awareness and demand are steadily increasing as healthcare systems modernize.
Middle East & Africa
The Middle East and Africa region presents a diverse and developing market for enteric empty capsules. The Gulf Cooperation Council (GCC) countries, with their higher healthcare spending, form the more advanced segment of the market, driven by a growing pharmaceutical industry and increasing imports of finished dosage forms. There is a specific demand for capsules compliant with Islamic (halal) requirements. In Africa, the market is nascent and highly fragmented, with growth primarily concentrated in more developed economies like South Africa. Market expansion is challenged by infrastructural limitations and less stringent regulatory frameworks in many countries. However, improving access to medicine and rising health awareness offer long-term growth potential, albeit from a relatively small base.
This market research report offers a holistic overview of global and regional markets for the forecast period 2025–2031. It presents accurate and actionable insights based on a blend of primary and secondary research.
✅ Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
✅ Segmentation Analysis
By product type: Gelatin Type, HPMC Type
By application: Pharmaceutical, Health Supplements, Others
✅ Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
✅ Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
✅ Technology & Innovation
Emerging capsule technologies and R&D trends
Automation and digitalization in manufacturing
✅ Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
✅ Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
✅ Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Pharmaceutical and biotech companies
Medical device and supplement manufacturers
Healthcare providers
Contract manufacturing organizations
Investors, consultants, and policy makers
-> Global enteric empty capsules market was valued at USD 86.6 million in 2024 and is projected to reach USD 254 million by 2031.
-> Key players include Capsugel, CapsCanada, Suheung, Qualicaps, and Anhui Huangshan Capsule, with top five companies holding about 90% market share.
-> The market is expected to grow at a CAGR of 17.0% during 2024-2031.
-> China is the largest market with 55% share, while North America and Europe collectively hold about 40%.
-> The market is segmented into Gelatin Type (75% share) and HPMC Type capsules.
Our Clients
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates